NALIRIFOX Clinical Trials
8 recruitingDrug
Phase 26Phase 14
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Metastatic Pancreatic CancerPancreatic AdenocarcinomaBasal Cell Neoplasm
UNC Lineberger Comprehensive Cancer Center104 enrolled1 locationNCT06483555
Recruiting
Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)387 enrolled11 locationsNCT06917079
Recruiting
Phase 2
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Northwell Health41 enrolled7 locationsNCT07163273
Recruiting
Phase 1
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
Pancreatic Ductal Adenocarcinoma (PDAC)
University of Colorado, Denver10 enrolled1 locationNCT07030283
Recruiting
Phase 2
NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
NENS
Second Affiliated Hospital, School of Medicine, Zhejiang University28 enrolled1 locationNCT07077551
Recruiting
Phase 2
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT05851924
Recruiting
Phase 2
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
Resectable Pancreatic Adenocarcinoma
Taichung Veterans General Hospital84 enrolled9 locationsNCT06816914
Recruiting
Phase 1Phase 2
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Pancreatic Cancer
University of Kansas Medical Center21 enrolled1 locationNCT06736717